OncoBay Clinical Appoints Lisa Zimmerman as VP of Regulatory and Quality Assurance
TAMPA, Fla. (February 15, 2021) — OncoBay Clinical, Inc., a full-service boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, today announced the appointment of Lisa Zimmerman to the position of Vice President, Regulatory Affairs and Quality Assurance reporting to Krystyna Kowalczyk, President and Chief Executive Officer.
“I am excited to join an organization such as OncoBay, where my personal and professional vision is aligned. I look forward to working together with this team where there is a clear roadmap to transform IO research through innovation, collaboration and partnership, and most importantly to positively impact cancer patients’ lives ,” said Zimmerman.
Lisa Zimmerman is an accomplished professional with a proven track record of success in Quality Assurance, Regulatory Affairs, Regulatory Compliance, and Clinical Operations in the in the Pharmaceutical, Device and Biotechnology industries. As a 27-year pharmaceutical veteran she brings to OncoBay, broad experience in all phases of drug and device development in multiple therapeutic areas, yet with a specialty in immune mediated diseases and oncology. Lisa has held senior leadership positions in Quality, Regulatory Affairs and Clinical Operations and has consulted with small pharmaceutical and biotechnology companies to assist in their navigation of the constantly evolving regulatory landscape across the globe. Ms. Zimmerman obtained her Bachelor of Science Degree in Biology from the University of North Carolina and attended Central Michigan University while pursuing her Master of Science in Business Administration in Healthcare.
“Lisa is an accomplished professional with a proven track record of success. We feel extremely fortunate to appoint someone of Lisa’s caliber and reputation in the field of oncology drug development,” said Krystyna Kowalczyk, President and CEO of OncoBay, “ As a critical member of our leadership team, Lisa will provide expert regulatory consultation, guidance and oversight to our Sponsors and Network Sites while leading the management and continual improvement of our organization-wide quality management system.”
To learn more about OncoBay Clinical, please visit www.OncoBay.com.
About OncoBay Clinical
OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full- service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit OncoBay.com and follow us on Facebook, Twitter and LinkedIn.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
OncoBay Clinical, Vice-President Business Operations